Overactive%20bladder News

Sleep disturbance appears to be common among individuals with overactive bladder (OAB), regardless of treatment, as reported in a study.

Mirabegron, a ß3 adrenoceptor agonist, delivers benefit for both men and women with overactive bladder (OAB) who are experiencing sexual dysfunction, a systematic review and meta-analysis reports.

Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.

Supplementation with vitamin D does not lead to improvements in overactive bladder or urinary incontinence relative to placebo, a study has shown. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels shows inconsistent results.

Some social needs that are not properly addressed may contribute to the presence of overactive bladder (OAB) in adults, and these unmet needs can affect the overall management of OAB patients, suggests a recent study.

The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.

Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).

The intravesical instillation of onabotulinumtoxinA (onabotA) for refractory overactive bladder in urinary incontinence is generally safe and well-tolerated, but demonstrates no significant efficacy advantage over placebo, according to a recent study.

Children with refractory overactive bladder (OAB) benefit from botulinum toxin-A (BTX-A) injections, which can safely enlarge bladder and suppress OAB symptoms, a recent study has found.

Prophylactic antibiotic works to prevent the development of urinary tract infection (UTI) following intravesical OnabotulinumtoxinA (BTX) injection, with a multiple-day regimen being as effective as a single-day regimen, according to a study.